Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 62
Filtrar
1.
Cancer Res ; 50(9): 2794-802, 1990 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-2158399

RESUMO

A neuroblastic-like cell line (NUB-20) was derived from a case of histopathologically diagnosed metastatic neuroblastoma. The metastatic tumor and nude mouse heterotransplant resembled neuroblastoma by histological criteria, in contrast to the primary tumor, which was differentially classified as Ewing's sarcoma. However, the cell line demonstrated a unique phenotype in culture with respect to morphology, immunohistochemical markers, and sensitivity to a battery of differentiation modulators. These characteristics, together with the presence of a chromosomal translocation (11;22),(q24;q12) and amplification with enhanced expression of the c-myc protooncogene rather than N-myc, established this tumor as neuroepithelioma. Neuroepithelioma is a tumor type distinct from, but related to, neuroblastoma in its development from the neural crest lineage. These results emphasize the growing importance of cytogenetic and molecular markers in the classification and characterization of human tumors.


Assuntos
Tumores Neuroectodérmicos Primitivos Periféricos/patologia , Bucladesina/farmacologia , Catecolaminas/análise , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Criança , Expressão Gênica , Humanos , Imuno-Histoquímica , Interferon Tipo I/farmacologia , Interferon gama/farmacologia , Masculino , Tumores Neuroectodérmicos Primitivos Periféricos/análise , Tumores Neuroectodérmicos Primitivos Periféricos/genética , Fenótipo , Proto-Oncogenes , Proteínas Recombinantes , Células Tumorais Cultivadas
2.
Leukemia ; 10(3): 460-5, 1996 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-8642862

RESUMO

Hematopoietic cells require certain cytokines to maintain viability by preventing apoptotic cell death. These cytokines can also protect leukemic cell lines against induction of apoptosis by cytotoxic anticancer compounds. We now show that the cytokines granulocyte-macrophage colony-stimulating factor and interleukin 3 can protect primary human myeloid leukemic cells against doxorubicin-induced apoptosis. Protection was detected in cells from 72% of the myeloid leukemic patients tested. The results indicate that these, and perhaps other, hematopoietic cytokines can decrease the effectiveness of cytotoxic anticancer therapy in some human myeloid leukemias. Leukemic cell sensitization to cytotoxic therapy may, therefore, require decreasing the availability of certain cytokines.


Assuntos
Antibióticos Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Doxorrubicina/farmacologia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/farmacologia , Interleucina-3/farmacologia , Leucemia Mieloide Aguda/patologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Sobrevivência Celular/efeitos dos fármacos , Criança , Dano ao DNA , DNA de Neoplasias/efeitos dos fármacos , DNA de Neoplasias/metabolismo , Feminino , Humanos , Leucemia Mieloide Aguda/metabolismo , Masculino , Pessoa de Meia-Idade , Células Tumorais Cultivadas/efeitos dos fármacos , Células Tumorais Cultivadas/metabolismo , Células Tumorais Cultivadas/patologia
3.
Leukemia ; 1(5): 437-41, 1987 May.
Artigo em Inglês | MEDLINE | ID: mdl-3312841

RESUMO

The ribonucleotide reductase inhibitors deferoxamine and hydroxyurea induce monocyte-macrophage cell differentiation in the leukemic cell line HL-60 as judged by the expression of cell surface antigens, nonspecific esterase activity, and morphological changes. Treatment of HL-60 cells with deferoxamine results in inhibition of DNA synthesis and irreversible loss of colony-forming ability. In addition, both deferoxamine and hydroxyurea caused an increase in the number of DNA strand breaks in HL-60 cells. A DNA methylating agent, N-methyl-N'-nitro-N-nitrosoguanidine, also caused cellular differentiation in HL-60 cells associated with DNA strand breaks. These observations are consistent with a role for DNA damage or for inhibition of DNA synthesis and repair in the differentiation process of HL-60 cells.


Assuntos
Ciclo Celular/efeitos dos fármacos , Reparo do DNA/efeitos dos fármacos , DNA de Neoplasias/biossíntese , Desferroxamina/farmacologia , Antígenos de Superfície/análise , Benzamidas/farmacologia , Diferenciação Celular/efeitos dos fármacos , Humanos , Hidroxiureia/farmacologia , Leucemia Mieloide Aguda/patologia , Metilnitronitrosoguanidina/farmacologia , Proteínas de Neoplasias/biossíntese , RNA Neoplásico/biossíntese , Ribonucleotídeo Redutases/antagonistas & inibidores , Células Tumorais Cultivadas
4.
Leukemia ; 16(8): 1413-8; discussion 1419-22, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12145678

RESUMO

Recurrent disease remains a major obstacle to cure after allogeneic transplantation. Various methods have been developed to detect minimal residual disease (MRD) after transplantation to identify patients at risk for relapse. Chimerism tests differentiate recipient and donor cells and are used to identify MRD when there are no other disease-specific markers. The detection of MRD does not always correlate with relapse risk. Chimerism testing may also identify normal hematopoietic cells or other cells not contributing to relapse. In this study we report our initial experience with a novel system that provides combined morphological and cytogenetical analysis on the same cells. This system allows rapid automatic scanning of a large number of cells, thus increasing the sensitivity of detection of small recipient population. The clinical significance of MRD detection is improved by identifying the morphology of recipient cells. Identification of recipient characteristics within blasts predicts overt relapse in leukemia patients and precedes it by a few weeks to months. Identification within mature hematopoietic cells may not be closely associated with relapse. The system also allows chimerism testing after sex-mismatched transplants, within cellular subsets, with no need for sorting of cells. The system merits further study in larger scale trials.


Assuntos
Exame de Medula Óssea/métodos , Transplante de Células-Tronco Hematopoéticas , Imuno-Histoquímica/métodos , Hibridização in Situ Fluorescente/métodos , Neoplasia Residual/diagnóstico , Quimeras de Transplante , Automação , Exame de Medula Óssea/instrumentação , Humanos , Imuno-Histoquímica/instrumentação , Hibridização in Situ Fluorescente/instrumentação , Leucemia Mieloide/diagnóstico , Leucemia Mieloide/patologia , Leucemia Mieloide/terapia , Linfoma não Hodgkin/diagnóstico , Linfoma não Hodgkin/patologia , Linfoma não Hodgkin/terapia , Masculino , Pessoa de Meia-Idade , Neoplasia Residual/patologia , Recidiva , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Transplante Homólogo/patologia
5.
Transplantation ; 70(7): 1100-4, 2000 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-11045650

RESUMO

BACKGROUND: Immunotherapy given post-autologous stem cell transplantation may eliminate residual tumor cells escaping the conditioning protocol. METHODS: Five children suffering from stage IV neuroblastoma were treated by recombinant interleukin-2 (IL-2) post-autologous peripheral blood stem cell transplantation. The patients' peripheral mononuclear cells were monitored for CD3+ and CD56+ levels, their proliferative response and killing of various cell lines targets. RESULTS: An increase in the level of total lymphocytes, mainly due to expansion of T cells, and enhanced proliferative response to phytohemaglutinin were observed. Elevated cytotoxicity against K562 and neuroblastoma target cells was detected in four patients and against K562 targets in one patient. Toxicity included mild thrombocytopenia, and fever in four patients and mild to moderate encephalopathy which necessitated withdrawing one patient from the protocol. Three of five patients studied are alive today, one of them whose IL-2 was stopped, is in relapse. Two patients have died. CONCLUSIONS: Immunotherapy with s.c. intermediate-high dose IL-2 is feasible and results in expansion of T cells and in stimulation of killing activity against several targets including in some cases, neuroblastoma tumor cells.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Interleucina-2/imunologia , Neuroblastoma/patologia , Neuroblastoma/cirurgia , Pré-Escolar , Relação Dose-Resposta Imunológica , Feminino , Transplante de Células-Tronco Hematopoéticas/mortalidade , Humanos , Imunoterapia , Lactente , Interleucina-2/uso terapêutico , Ativação Linfocitária/efeitos dos fármacos , Masculino , Estadiamento de Neoplasias , Taxa de Sobrevida , Linfócitos T/imunologia , Fatores de Tempo , Transplante Autólogo
6.
Pediatrics ; 65(4): 782-8, 1980 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-7367085

RESUMO

A brother and sister who suffered from pruritus since infancy developed hepatic cirrhosis early in life. Although this clinical picture has never been seen in Wilson's disease, Kayser-Fleischer rings in the boy made further studies necessary. Oral radiocopper loading tests administered to both children and to their parents served to exclude Wilson's disease conclusively. Determinations of the concentrations and patterns of bile acids in the serum indicated that the abnormalities observed in these children are not related to errors in bile acid synthesis. Although a defect in bile acid transport is present, it appears to have occurred as a consequence of the liver disease.


Assuntos
Colestase/genética , Doenças da Córnea/etiologia , Cirrose Hepática/genética , Criança , Colestase/diagnóstico , Diagnóstico Diferencial , Feminino , Degeneração Hepatolenticular/diagnóstico , Humanos , Fígado/patologia , Masculino , Síndrome
7.
Bone Marrow Transplant ; 34(4): 317-20, 2004 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-15220954

RESUMO

Successful stem cell transplantation for patients with severe combined immunodeficiency (SCID) from matched family donors without conditioning results in engraftment of T lymphocytes. B lymphocytes engraft in only 50% of the cases, while myelopoiesis and erythropoiesis remain of host origin. Full hematopoietic engraftment was reported in one case after bone marrow transplantation without conditioning for a SCID patient. We studied three SCID patients who were transplanted with unmodified mobilized peripheral blood from HLA-identical family sex-mismatched members. They received megadoses of stem cells (18-23 x 10(6)CD34/kg). In contrast to the expected mixed chimerism that usually occurs in the absence of conditioning, we found in our patients 100% donor cell engraftment based on fluorescence in situ hybridization (FISH) and microsatellite techniques. Subset analysis of the engrafted cells using a multiparametric system enabling a combined analysis of morphology, immunophenotyping and FISH showed that both T and B lymphocytes and myeloid cells were of donor origin in two patients, while T lymphocytes and myeloid cells were of donor origin in the third. In the two cases with ABO incompatibility, erythroid engraftment was evidenced by blood group conversion from recipient to donor type. Multilineage donor engraftment is possible in SCID patients even without conditioning.


Assuntos
Transfusão de Linfócitos , Imunodeficiência Combinada Severa/terapia , Transplante de Células-Tronco/métodos , Linfócitos B/transplante , Transplante de Medula Óssea/imunologia , Criança , Pré-Escolar , Família , Feminino , Antígenos HLA/imunologia , Teste de Histocompatibilidade , Humanos , Lactente , Masculino , Imunodeficiência Combinada Severa/imunologia , Linfócitos T/transplante , Condicionamento Pré-Transplante , Transplante Homólogo , Resultado do Tratamento
8.
Bone Marrow Transplant ; 32(1): 31-4, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12815475

RESUMO

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is frequently used to mobilize CD34+ cells in healthy donors and patient with malignant diseases prior to peripheral blood stem cell (PBSC) harvest. To analyze the effects of rhG-CSF on morphology and genotype of white blood cells, a novel multiparametric cell scanning system that combines morphologic, immune and genotypic analyses of the same cells was used. We report here that tetraploid myeloid cells are present in the peripheral blood of donors treated with rhG-CSF. The tetraploidy was detected in up to 0.6% of differentiated myeloid cells and all observed CD34+ cells were diploid. Thus, short treatment with rhG-CSF of PBSC donors induces numerfical chromosomal alterations in a small subset of mature myeloid cells.


Assuntos
Fator Estimulador de Colônias de Granulócitos/farmacologia , Mobilização de Células-Tronco Hematopoéticas/métodos , Células Mieloides/efeitos dos fármacos , Poliploidia , Doadores de Tecidos , Estudos de Casos e Controles , Tamanho Celular/efeitos dos fármacos , Aberrações Cromossômicas/induzido quimicamente , Análise Citogenética , Avaliação de Medicamentos , Feminino , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Células Precursoras de Granulócitos/citologia , Células Precursoras de Granulócitos/efeitos dos fármacos , Humanos , Leucaférese , Linfoma/terapia , Masculino , Células Mieloides/citologia , Neutrófilos/citologia , Neutrófilos/efeitos dos fármacos , Transplante de Células-Tronco de Sangue Periférico/métodos , Proteínas Recombinantes
9.
Bone Marrow Transplant ; 23(4): 405-8, 1999 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10100587

RESUMO

A 2-month-old girl with severe combined immunodeficiency (SCID), presented with mild staphylococcal skin infection, lymphopenia, low T cell number, absence of B cells, high number of NK cells, and a negligible response to mitogens. Since her older brother died as a result of SCID 2 years earlier, cord blood was harvested from a sister born 2 1/2 years earlier, who was normal and fully matched both by serology and molecular typing. In view of her clinical condition and in spite of a high number of NK cells with normal activity, HUCBT without preparative conditioning was performed. No G-CSF was administered. Engraftment with mixed chimerism was evident 3 weeks post transplantation. There were no peritransplantation complications. Eighteen months post transplantation, the girl is in excellent condition, blood counts are normal, T cell engraftment is complete, B cell engraftment is proceeding gradually, and the mitogen stimulation tests are normal. Due to the unique nature of HUCB hematopoietic cells, engraftment without conditioning may be possible in patients with SCID with fully matched donors. This is the first HUCBT performed without conditioning.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Imunodeficiência Combinada Severa/imunologia , Imunodeficiência Combinada Severa/terapia , Feminino , Sangue Fetal , Sobrevivência de Enxerto , Humanos , Lactente , Transplante Homólogo
10.
Cancer Genet Cytogenet ; 75(1): 11-22, 1994 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-8039158

RESUMO

The cytogenetic findings of therapy-related myeloid leukemia (t-ML) in three children are presented. These included one male patient with acute lymphoblastic leukemia (ALL) who underwent bone marrow transplantation and developed therapy-related myeloproliferative disease (t-MPD) in the female-donor hematopoietic cells 2.5 years after receiving radiation and epipodophyllotoxin therapy for ALL testicular relapse. Bone marrow leukemic cell karyotype revealed 46,XX,add (11)(p15) and a normal female karyotype in the peripheral blood lymphocytes. The other two children, one with ALL and one with ganglioneuroblastoma, developed fatal t-MPD and therapy-related acute myeloblastic leukemia (t-AML) preceded by myelodysplastic syndrome (t-MDS), respectively, 5 years after diagnosis, following administration of alkylating agents and irradiation. Monosomy 7 was present in both, and was combined with inv(3)(q21q26) in the second patient. Our review of the cytogenetic findings in 91 previously reported pediatric patients with t-ML suggested that the involvement of 11p15 and 3q21-->23, 3q24-q26 with or without a combination of translocation 11q23 and -7/7q-, respectively, are nonrandom aberrations of t-ML in children. Comparison of the chromosomal changes in t-ML between the pediatric and an adult series revealed some differences which may result from differences in treatment modalities and which, in addition, may indicate a possible role of genetic and/or age-dependent factors in the pathogenesis of therapy-related leukemogenesis in children.


Assuntos
Antineoplásicos/efeitos adversos , Aberrações Cromossômicas , Cromossomos Humanos Par 11 , Cromossomos Humanos Par 3 , Leucemia Mieloide/genética , Segunda Neoplasia Primária/genética , Pré-Escolar , Feminino , Humanos , Lactente , Leucemia Mieloide/etiologia , Masculino , Segunda Neoplasia Primária/etiologia , Translocação Genética
11.
Cancer Chemother Pharmacol ; 17(3): 264-8, 1986.
Artigo em Inglês | MEDLINE | ID: mdl-3742712

RESUMO

Tubercidin, an adenosine analogue, is toxic to human neuroblastoma cell lines, to peripheral blood mononuclear cells (PBMCs), and to myeloid colony-forming cells (CFU-C) as tested by a short-term labeled precursor uptake and by a clonogenic assay. When it was co-administered with a potent purine transport inhibitor, nitrobenzyl thioinosine (NBTI), the cytotoxic effect of tubercidin was abolished in PBMCs but not in neuroblastoma cells. Studies of nucleoside transport in neuroblastoma cells demonstrate that although [3H]NBTI binds to the plasma membrane of these cells, the transport of thymidine into the cells is only partially inhibited in the presence of excess NBTI. These data imply that neuroblastoma cells contain a nucleoside transport mechanism which is insensitive to NBTI. "Host protection" with a nucleoside transport inhibitor such as NBTI, may allow effective therapy with otherwise toxic dosages of tubercidin and other cytotoxic nucleosides in patients with neuroblastoma.


Assuntos
Inosina/análogos & derivados , Linfócitos/efeitos dos fármacos , Neuroblastoma/tratamento farmacológico , Ribonucleosídeos/farmacologia , Tioinosina/análogos & derivados , Tubercidina/farmacologia , Transporte Biológico/efeitos dos fármacos , Linhagem Celular , Ensaio de Unidades Formadoras de Colônias , Humanos , Neuroblastoma/metabolismo , Tioinosina/farmacologia , Timidina/metabolismo , Tubercidina/antagonistas & inibidores , Ensaio Tumoral de Célula-Tronco
12.
Leuk Lymphoma ; 14(1-2): 49-53, 1994 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-7920228

RESUMO

The non-Hodgkin's lymphomas of childhood and adolescence are a heterogeneous group of diseases that constitute 7-10 percent of all pediatric malignancies. Major strides have been made in recent years in understanding the pathogenesis of lymphomas at a molecular level but have not yet led to a modification of clinical management. Between 1973 and 1992, 112 children with B-cell non-Hodgkin's lymphoma were diagnosed. The median age was 5.7 years, with male to female ratio of 3 to 1. Fifty percent presented with abdominal masses, mostly confined to the ileo-ceccal region and to the retroperitoneum. In 39 percent there was head and neck involvement, with 15 percent jaw lesions. Until 1978 patients were treated with the Beilinson Medical Center (BMC) protocol, which yielded only 26 percent disease-free survival for stage IV patients. The introduction of the LMB-86 regimen significantly improved the disease-free survival of patients with advanced stage III and IV disease (84 and 68 percent, respectively). Bone marrow (over 70 percent blasts) and central nervous system involvement remain the major prognostic criteria.


Assuntos
Linfoma de Células B/epidemiologia , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma de Burkitt/tratamento farmacológico , Linfoma de Burkitt/epidemiologia , Linfoma de Burkitt/patologia , Criança , Pré-Escolar , Ensaios Clínicos como Assunto , Terapia Combinada , Feminino , Humanos , Lactente , Israel/epidemiologia , Linfoma de Células B/tratamento farmacológico , Linfoma de Células B/patologia , Linfoma de Células B/radioterapia , Masculino , Estudos Multicêntricos como Assunto , Estadiamento de Neoplasias , Estudos Retrospectivos , Resultado do Tratamento
13.
Clin Cardiol ; 14(8): 696-8, 1991 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-1914276

RESUMO

We present 2 cases in whom repetitive rapid ventricular tachycardia (VT) was the initial manifestation of metastatic cardiac disease. In one patient, repetitive VT appeared during chemotherapy for stage IV paratesticular rhabdomyosarcoma which led to the diagnosis of cardiac metastases. In the other, it led to the diagnosis of malignant pericardial effusion 17 years after successful therapy for a breast carcinoma. In conclusion, in patients with present or past history of malignancy, the appearance of life-threatening VT should raise the suspicion of cardiac metastases.


Assuntos
Neoplasias Cardíacas/complicações , Taquicardia/etiologia , Adulto , Ecocardiografia , Eletrocardiografia , Feminino , Neoplasias Cardíacas/diagnóstico por imagem , Neoplasias Cardíacas/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Taquicardia/diagnóstico , Taquicardia/terapia
14.
J Pediatr Ophthalmol Strabismus ; 15(4): 239-45, 1978.
Artigo em Inglês | MEDLINE | ID: mdl-216790

RESUMO

A case of Neonatal Herpes Simlex Virus (RSV) Encephalitis with severe ocular manifestation treated by topical systemic and intrathecal Interferon inducer, Poly IC (Polyriboinosinic acid-Polyribocytidylic acid) is reported. Prior to the administration of Poly IC, no Interferon could be detected neither in blood nor in CSF and vesicular fluid from conjunctiva. Intravenous administration of the drug initiated measurable levels in blood and tears, but not in CSF. However, intrathecal injection induced persistent high levels of Interferon in CSF. Virus clearance from conjunctiva tears and vesicular fluid occurred after three days of topical application of Poly IC. The mechanism of action of Poly IC, the laboratory results and the therapeutic conclusions are discussed in detail. This is the first report of intrathecal administration of Poly IC in a case of HSV Encephalitis.


Assuntos
Encefalite/tratamento farmacológico , Indutores de Interferon/uso terapêutico , Ceratite Dendrítica/tratamento farmacológico , Encéfalo/patologia , Coriorretinite/complicações , Encefalite/diagnóstico , Encefalite/patologia , Feminino , Humanos , Lactente , Recém-Nascido , Injeções Espinhais , Indutores de Interferon/farmacologia , Interferons/sangue , Ceratite Dendrítica/diagnóstico , Masculino , Simplexvirus/isolamento & purificação
15.
Harefuah ; 137(12): 609-11, 679, 1999 Dec 15.
Artigo em Hebraico | MEDLINE | ID: mdl-10959385

RESUMO

Hemophagocytic syndrome is a rare, fulminant disease characterized by generalized histiocytic proliferation associated with phagocytosis of erythrocytes, platelets, and to a lesser extent, of white blood cells. We report a 2-year-old boy admitted with high fever and irritability, with a rash, marked hepatomegaly and generalized lymphadenopathy. Liver function tests were abnormal and there was thrombocytopenia and hyperlipidemia. Bone marrow aspiration revealed hemophagocytosis. Despite intensive treatment with steroids, intravenous immunoglobulin and cytotoxic drugs, he died within 10 weeks.


Assuntos
Histiocitose de Células não Langerhans/diagnóstico , Medula Óssea/patologia , Etoposídeo/uso terapêutico , Evolução Fatal , Histiocitose de Células não Langerhans/tratamento farmacológico , Histiocitose de Células não Langerhans/patologia , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Lactente , Masculino , Metilprednisolona/uso terapêutico
19.
20.
Harefuah ; 129(9): 346-50, 1995 Nov 01.
Artigo em Hebraico | MEDLINE | ID: mdl-8549988
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA